- Exome and genome in neonatal screening and EIM: scope and limitations.
- Technological advances in neonatal screening and new diagnostic methods, including omics.
- Artificial intelligence linked to neonatal screening and diagnosis for EIM.
- Ethical, legal and social implications in neonatal screening and EIM.
- State of the art of neonatal screening in Latin America.
- Networks in Latin America to optimize resources in neonatal screening and in the diagnosis and treatment of EIM.
- Basic panels in neonatal screening and new disorders to be incorporated (e.g., SMA, SCID, ADL-X).
- Evaluation and quality management in the laboratory.
- Lysosomal diseases: from neonatal screening to treatment.
- New therapeutic modalities for IEM (gene therapy, RNA-based medicine, and others).
- New treatments for intermediary metabolism diseases.
- Congenital defects of glycosylation and new genetic technologies for their diagnosis.
- Disorder of brain creatine metabolism: neonatal screening, diagnostic confirmation and therapeutic advances.
- Clinical approach and diagnosis of neurotransmitter defects.
- Metabolic disorders of vitamins, cofactors and trace elements.
- Peroxisomal metabolism, bile acids and lipoproteinies.
- Clinical approach and neonatal screening of: amino acid disorders, urea cycle defects, beta oxidation defects, organic acidurias.
- Advances in the diagnosis and treatment of mitochondrial diseases.
- IEM in adults
- IEM: Newly described diseases.
- Educational tools for patients and their families in rare diseases.
- Telemedicine in EIM: challenges, promises and realities.
